Acenocoumarol
Adverse Effect: An increased risk of bleeding Clinical Management: In patients receiving oral anticoagulant therapy, the prothrombin time ratio or INR (international normalized ratio) should be closely monitored with the addition and withdrawal of treatment with Cisapride, and should be reassessed periodically during concurrent therapy. Adjustments of the Acenocoumarol dose may be necessary in order to maintain the desired level of anticoagulation.
Amiodarone
Adverse Effect: cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: The concurrent use of cisapride and Amiodarone is contraindicated.
Amitriptyline
Adverse Effect: cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: The concurrent use of cisapride and Amitriptyline is contraindicated.
Astemizole
Adverse Effect: cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: The concurrent use of cisapride and astemizole is contraindicated.
Atropine
Adverse Effect: Loss of cisapride efficacy Clinical Management: The beneficial effects of cisapride are expected to be largely lost if an anticholinergic medication such as atropine is given concomitantly.
Chlordiazepoxide
Adverse Effect: Cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: The concurrent use of cisapride and Chlordiazepoxide contraindicated.
Cimetidine
Adverse Effect: Cisapride toxicity (dizziness, tachycardia, GI discomfort) Clinical Management: Monitor for potential cisapride toxicity (eg, dizziness, tachycardia, & GI discomfort) and adjust the dose accordingly. If concurrent use cannot be avoided, select another H2-antagonist (eg, ranitidine or famotidine) that has less potential to alter the pharmacokinetics of cisapride.
Clarithromycin
dverse Effect: cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: Coadministration of cisapride with clarithromycin is contraindicated. Serious, even fatal, adverse cardiac events have been reported when these agents were given concomitantly.
Clidinium Br.
Adverse Effect: Loss of cisapride efficacy Clinical Management: The beneficial effects of cisapride are expected to be largely lost if an anticholinergic medication such as clidinium is given concomitantly.
Clomipramine
Adverse Effect: cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: The concurrent use of cisapride and Clomipramine is contraindicated.
Cyclopentolate
Adverse Effect: Loss of cisapride efficacy Clinical Management: The beneficial effects of cisapride are expected to be largely lost if an anticholinergic medication such as cyclopentolate is given concomitantly.
Dicyclomine
Adverse Effect: Loss of cisapride efficacy Clinical Management: The beneficial effects of cisapride are expected to be largely lost if an anticholinergic medication such as dicyclomine is given concomitantly.
Digoxin
Adverse Effect: Decreased digoxin effectiveness Clinical Management: This interaction appears to be minimal and is not expected to significantly alter the clinical efficacy of digoxin therapy.
Diltiazem
Adverse Effect: an increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: Combination therapy with diltiazem and cisapride should be avoided. If the concomitant administration of cisapride and diltiazem is deemed clinically necessary, closely monitor the electrocardiogram (ECG).
Disopyramide
Adverse Effect: cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: The concurrent use of cisapride and Disopyramide is contraindicated.
Dothiepin
Adverse Effect: cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: The concurrent use of cisapride and Dothiepin is contraindicated.
Doxepin
Adverse Effect: cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: The concurrent use of cisapride and Doxepin is contraindicated.
Efavirenz
Adverse Effect: Efavirenz causes inhibition of isoenzyme CYP3A4 Cisapride is mainly metabolized via CYP3A4 so it leads to reducing the clearance of Cisapride resulting in serious adverse events. # Clinical Management: Avoid concomitant use of Cisapride and Efavirenz.
Erythromycin
Adverse Effect: cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: Coadministration of cisapride with erythromycin is contraindicated by the manufacturer of cisapride. Serious, even fatal, adverse events have been reported when these agents were given concomitantly.
Fluconazole
Adverse Effect: cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: Coadministration of cisapride and fluconazole is contraindicated.
Fluphenazine
Adverse Effect: cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: The concurrent use of cisapride and phenothiazines is contraindicated.
Frusemide
Hypokalaemia induced by diurectic
Glycopyrrolate
Adverse Effect: Loss of cisapride efficacy Clinical Management: The beneficial effects of cisapride are expected to be largely lost if an anticholinergic medication such as glycopyrrolate is given concomitantly.
Haloperidol
Adverse Effect: Worsening of psychotic symptoms Clinical Management: Monitor patients for worsening of psychotic symptoms if cisapride is added to haloperidol therapy.
Homatropine
Adverse Effect: Loss of cisapride efficacy Clinical Management: The beneficial effects of cisapride are expected to be largely lost if an anticholinergic medication such as homatropine is given concomitantly.
Hyoscine Butyl. Br.
Adverse Effect: Loss of cisapride efficacy Clinical Management: The beneficial effects of cisapride are expected to be largely lost if an anticholinergic medication such as butylscopolamine is given concomitantly.
Imipramine
Adverse Effect: cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: The concurrent use of cisapride and Imipramine is contraindicated.
Ipratropium Br.
Adverse Effect: Loss of cisapride efficacy Clinical Management: The beneficial effects of cisapride are expected to be largely lost if an anticholinergic medication such as ipratropium is given concomitantly.
Isopropamide
Adverse Effect: Loss of cisapride efficacy Clinical Management: The beneficial effects of cisapride are expected to be largely lost if an anticholinergic medication such as isopropamide is given concomitantly.
Itraconazole
Adverse Effect: An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: Coadministration of cisapride with itraconazole is contraindicated.
Ketoconazole
Adverse Effect: cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: Coadministration of cisapride with ketoconazole is contraindicated by the manufacturer of cisapride. Serious, even fatal, adverse events have been reported when these agents were given concomitantly.
Levodopa
Adverse Effect: An increased risk of levodopa adverse effects (abnormal involuntary movements, tremor, nausea and vomiting, cardiovascular stimulation) Clinical Management: Monitor patients for excessive levodopa adverse effects (abnormal involuntary movements, tremor, nausea and vomiting, cardiovascular stimulation) if cisapride is being concurrently administered.
Nortriptyline
Adverse Effect: cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: The concurrent use of cisapride and Nortriptyline is contraindicated.
Oxybutynin
Adverse Effect: Loss of cisapride efficacy Clinical Management: The beneficial effects of cisapride are expected to be largely lost if an anticholinergic medication such as oxybutynin is given concomitantly.
Phenindione
Adverse Effect: Increased risk of bleeding Clinical Management: In patients receiving oral anticoagulant therapy, the prothrombin time ratio or INR (international normalized ratio) should be closely monitored with the addition and withdrawal of treatment with cisapride, and should be reassessed periodically during concurrent therapy. Adjustments of the phenindione dose may be necessary in order to maintain the desired level of anticoagulation.
Pimozide
Adverse Effect: Increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: Pimozide is contraindicated in individuals with congenital QT syndrome, patients with a history of cardiac arrhythmias, or patients taking other drugs which may prolong the QT interval.
Procainamide
Adverse Effect: Cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: The concurrent use of cisapride and Procainamide is contraindicated.
Procyclidine
Adverse Effect: Loss of cisapride efficacy Clinical Management: The beneficial effects of cisapride are expected to be largely lost if an anticholinergic medication such as procyclidine is given concomitantly.
Propantheline Br.
Adverse Effect: Loss of cisapride efficacy Clinical Management: The beneficial effects of cisapride are expected to be largely lost if an anticholinergic medication such as propantheline is given concomitantly.
Propantheline Br. - Antispas
Adverse Effect: Loss of cisapride efficacy Clinical Management: The beneficial effects of cisapride are expected to be largely lost if an anticholinergic medication such as propantheline is given concomitantly.
Quinidine
Adverse Effect: cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: The concurrent use of cisapride and Quinidine is contraindicated.
Sotalol
Adverse Effect: cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: The concurrent use of cisapride and Sotalol is contraindicated.
Sparfloxacin
Adverse Effect: cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: Sparfloxacin is contraindicated in individuals with known QTc prolongation or in patients being treated concurrently with drugs that are known to increase the QTc interval and/or cause torsades de pointes, including cisapride
Terfenadine
Adverse Effect: prolongation of the QTc interval and/or torsades de pointes Clinical Management: Concomitant use of terfenadine and cisapride is not recommended.
Thioridazine
Adverse Effect: cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: The concurrent use of cisapride and phenothiazines is contraindicated.
Trifluoperazine
Adverse Effect: cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: The concurrent use of cisapride and Trifluoperazine is contraindicated.
Trihexiphenidyl
Adverse Effect: Loss of cisapride efficacy Clinical Management: The beneficial effects of cisapride are expected to be largely lost if an anticholinergic medication such as trihexyphenidyl is given concomitantly.
Trimipramine
Adverse Effect: cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Clinical Management: The concurrent use of cisapride and tricyclic antidepressants is contraindicated.
Tropicamide
Adverse Effect: Loss of cisapride efficacy Clinical Management: The beneficial effects of cisapride are expected to be largely lost if an anticholinergic medication such as tropicamide is given concomitantly.
Warfarin
Adverse Effect: Increased risk of bleeding Clinical Management: In patients receiving oral anticoagulant therapy with warfarin, the prothrombin time ratio or INR (international normalized ratio) should be closely monitored with the addition and withdrawal of treatment with cisapride, and should be reassessed periodically during concurrent therapy. Adjustments of the warfarin dose may be necessary in order to maintain the desired level of anticoagulation. |